Affimed Announces Abstracts on Innate Cell Engagers from its ROCK® Platform Accepted for Presentation at AACR Virtual Annual Meeting II May 15, 2020
Affimed Announces First Patient Successfully Dosed in First-in-Human Phase 1/2A Study of AFM24 for the Treatment of Advanced EGFR-Expressing Solid Tumors Including Colon, Lung and Other Cancers April 16, 2020
Affimed Provides COVID-19-Related Business Update and Announces Full Year 2019 Financial Results Conference Call on April 28, 2020 April 2, 2020
Affimed Announces FDA Granted Orphan Drug Designation for Lead Innate Cell Engager AFM13 for the Treatment of T-cell Lymphoma April 2, 2020
Affimed Announces Appointment of Arndt Schottelius, M.D. Ph.D. as Chief Scientific Officer March 17, 2020
